Healthcare

This issue of Vital Signs, released on September 30, 2013, provides a market overview and drug pipeline analysis of Type 2 diabetes therapeutics. Additionally, a company spotlight is provided for Trovagene in San Diego, CA. The company has a proprietary transrenal nucleic acid platform with the potential to deliver superior molecular diagnostics i...

This issue of Vital Signs, released on September 30, 2013, discusses perspectives of different Frost & Sullivan analysts on recent noteworthy news items for various markets including Pharma/Biotech, In Vitro Diagnostics, Advanced Medical Technology and Connected Health.

This study provides a roadmap for understanding the patient engagement movement and the use of patient portal technology by hospitals and physicians as the essential tool to drive that process. Included is an overview of macro trends in patient engagement and a comprehensive look at key features and functions associated with patient portals. Major ...

This research service pertains to the US market for medical radiopharmaceuticals. A thorough market sizing and forecasting model of market revenue, procedure volumes, and average pricing is included, along with analyses of market trends, drivers and restraints, and the reimbursement and the competitive environments at the total level as well as wit...

Given the importance of the changes from PPACA and the creation of the health insurance marketplaces, we are providing our online Frost.com blog on HIX in collected form for the month of August for ease of use by our subscription clients. This discussion is brought to you by our Connected Health research program. Please also follow our blog, part o...

The following Vital Signs presents analyst perspectives from our attendance at ACE 2013. The Allscripts Client Experience (ACE) is the companys annual user conference, held this year in Chicago, August 21-23. It offers registrants access to educational sessions, networking opportunities and more. During the event, Allscripts shows clients how to g...

The overall research objective was to capture and analyze global next-generation (NGS) sequencing trends and use. Most researchers outsource NGS technologies; however, in-house NGS technology use is expected to increase within the next 12 months. Data accuracy and operating costs are the top criteria for purchasing sequencing instruments. Disease-r...

This issue of Vital Signs, released on August 31, 2013, discusses perspectives of different Frost & Sullivan analysts on recent noteworthy news items for various markets including Pharma/Biotech, Advanced Medical Technology and Connected Health.

This issue of Vital Signs, released on August 31, 2013, explores the needs of an ever-expanding healthcare IT and interactive domain in a patient-centric model and identifies the criteria for true intelligent systems that are defining new approaches to care, facilitating the gathering and array of health information, including population management...